



**A CLINICAL PHASE BIOPHARMACEUTICAL COMPANY
WITH MULTIPLE PLATFORM TECHNOLOGIES
FOR THE TARGETED DELIVERY OF VACCINES AND OTHER
THERAPEUTICS**

Ines Atmosukarto, PhD

Chief Executive Officer

ines@lipotek.com.au

Australasian Life Science Investment Summit,
Adelaide 2011



Ines Atmosukarto ines@lipotek.com.au

www.lipotek.com.au



Versatile IP position with initial application in vaccines and immunotherapies Clinical Phase candidate in oncology

Key highlights


- 2004 Publication in *Cancer Research* – validation of lead platform technology
- 2004 **Domantis Ltd** Collaboration
- 2009 Phase I trial initiated (Malignant Melanoma)
- 2009 **PT Bio Farma** collaboration initiated, Indonesia
- 2010 **GSK** POC collaboration initiated (vaccine, siRNA, small molecules)
- 2011 advanced discussions, Indonesian Pharma

Business model

- Develop lead program for each platform & generate proof-of-concept human data
- Seek non-exclusive partnerships for products based on platform
- Partner early to co-develop product of interest to pharma
- Exploit links with pharma in SE Asia region - smaller industry but eager to access new IP




THE PIPELINE






LEAD PLATFORM - LIPOVAXIN

3-NTA-DTDA chelator lipid can be inserted into the lipid bilayer of liposomes




- Cargo can include: **cell-derived material, recombinant proteins, nucleic acids, small molecules**
- Lipid composition tailored to specific application






LIPOTEK'S APPROACH TO VACCINE DESIGN





LEAD PRODUCT: LIPOVAXIN-MM AN EXPERIMENTAL IMMUNOTHERAPY FOR MALIGNANT MELANOMA



Phase I trial (Sept 09 - 2011)

- 12 patients on study
- Vaccine well tolerated
- Indication of clinical response in some patients

- No ex vivo patient DC manipulation necessary
- Simple administration, intravenous
- Off-the-shelf formulation possible

The same approach can be used to deliver a mixture of other cancer antigens to DCs → independent products based on same approach

Seek new collaborators to explore other applications




FINANCIALS

Market Valuation	To be negotiated
Cash raised to date	\$7m *
Cash on hand	\$400K
Burn rate	Runway 12+ months

Revenue source from program extensions during FY2012	GlaxoSmithKline Bio Farma <i>Indonesia</i>
--	---

Investment sought	\$ 1-2m
-------------------	---------

Ownership structure



* Non-diluting equity from significant government and private foundation sources.

Includes: ACT Government, BIF, ComReady, ClimateReady, ATO, Gates Foundation.